Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.
Other analysts have also issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $6.00 price target on shares of Citius Pharmaceuticals in a research note on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research note on Friday, March 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a research note on Monday. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Citius Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.00.
Check Out Our Latest Report on Citius Pharmaceuticals
Citius Pharmaceuticals Trading Up 4.7%
Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.67). The firm had revenue of $1.67 million during the quarter, compared to analyst estimates of $10.23 million. Equities analysts forecast that Citius Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Citius Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in Citius Pharmaceuticals in the second quarter worth $32,000. NewEdge Advisors LLC acquired a new position in Citius Pharmaceuticals in the second quarter worth $40,000. Asset Advisory Group Inc. acquired a new position in Citius Pharmaceuticals in the fourth quarter worth $46,000. Finally, Heights Capital Management Inc. acquired a new position in Citius Pharmaceuticals in the fourth quarter worth $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.
Key Citius Pharmaceuticals News
Here are the key news stories impacting Citius Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright reaffirmed a Buy rating on Citius Pharmaceuticals and maintained a $4.00 price target, signaling meaningful upside potential from current levels. Citius Pharmaceuticals’ (CTXR) “Buy” Rating Reaffirmed at HC Wainwright
- Neutral Sentiment: The firm also issued updated earnings estimates for FY2026 and FY2027, with expectations for ongoing losses, including FY2026 EPS of ($1.87) and FY2027 EPS of ($0.81). While these forecasts show improvement over time, they still reflect a pre-profit company. HC Wainwright earnings estimate updates for Citius Pharmaceuticals
- Neutral Sentiment: HC Wainwright’s quarterly projections for Citius Pharmaceuticals remain negative across the forecast period, including Q3 2026 EPS of ($0.36), Q4 2026 EPS of ($0.25), Q1 2027 EPS of ($0.28), Q2 2027 EPS of ($0.20), Q3 2027 EPS of ($0.19), and Q4 2027 EPS of ($0.16). HC Wainwright quarterly earnings estimates for Citius Pharmaceuticals
About Citius Pharmaceuticals
Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.
One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.
Featured Articles
- Five stocks we like better than Citius Pharmaceuticals
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
